News

The company secured final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for this product, which is indicated to treat

At present there are few adequate and well-controlled studies of pharmacotherapy in preschool-age children with ADHD and the company is the process of developing design protocols for three

As part of the deal, MorphoSys and Merck’s biopharmaceutical division Merck Serono, will join forces to develop therapies that modulate the immune system’s natural ability to combat tumors.

After reviewing the company’s Clinical Trial Application, CCMO has provided a Letter of No Objection, and the Independent Ethics Committee of the Foundation "Evaluation of Ethics in Biomedical

NUVISAN is a fully integrated contract research organization providing clinical development and lab services to the global pharmaceutical industry. For over 30 years, NUVISAN has been assisting their

Ferrer, a privately-help Spanish pharmaceutical company, licensed US rights for Ozenoxacin to Medimetriks earlier this year. The multicenter, randomized, double-blinded, clinical study compares Ozenoxacin 1% cream versus placebo.

The McSwiggen patent estate broadly describes chemical modifications of RNAi therapeutics needed to achieve "drug-like" properties in siRNA, the molecules that mediate RNAi. Specifically, the ‘277 patent includes

On May 1, 2014 Parion announced FDA Acceptance of the Investigational New Drug Application for clinical testing of P-321 Ophthalmic Solution for the Treatment of Dry Eye Disease.

DiaPep277 is currently being evaluated in a fully enrolled confirmatory Phase 3 clinical study in adult patients, with results anticipated in the first quarter of 2015. DiaPep277 holds